These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2983127)

  • 41. A classification of HTLV-III infection based on 75 cases seen in a suburban community.
    Kaplan MH; Pahwa SG; Popovic M; Sarngadharan MG; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4655s-4658s. PubMed ID: 2990703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virologic studies of HTLV-III/LAV in pregnancy: case report of a woman with AIDS.
    Rogers MF; Ewing EP; Warfield D; Hardy AM; Emery DR; Wolf GC
    Obstet Gynecol; 1986 Sep; 68(3 Suppl):2S-6S. PubMed ID: 3016628
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serological differences between human T-lymphotropic virus type-I (HTLV-I) and HTLV-III/LAV.
    Harada S; Purtilo DT; Koyanagi Y; Yamamoto N
    Microbiol Immunol; 1986; 30(6):533-44. PubMed ID: 3018457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum interferon and clinical manifestations of infection with human T-lymphotropic virus type III.
    Abb J
    Med Microbiol Immunol; 1985; 174(4):205-10. PubMed ID: 2999573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural and epidemiological features of primate lymphotropic retroviruses.
    Hunsmann G; Schneider J; Bayer H; Jurkiewicz E; Yamamoto N
    Princess Takamatsu Symp; 1984; 15():109-18. PubMed ID: 6100632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
    Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
    Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications.
    Weiss SH; Goedert JJ; Sarngadharan MG; Bodner AJ; Gallo RC; Blattner WA
    JAMA; 1985 Jan; 253(2):221-5. PubMed ID: 2981369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implications of the discovery of HTLV-III for the treatment of AIDS.
    Yarchoan R; Mitsuya H; Matsushita S; Broder S
    Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Occupational risk of the acquired immunodeficiency syndrome among health care workers.
    McCray E
    N Engl J Med; 1986 Apr; 314(17):1127-32. PubMed ID: 3485769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HTLV-III in the tears of AIDS patients.
    Fujikawa LS; Salahuddin SZ; Ablashi D; Palestine AG; Masur H; Nussenblatt RB; Gallo RC
    Ophthalmology; 1986 Dec; 93(12):1479-81. PubMed ID: 3643502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Molecular biology of human T-lymphotropic retroviruses (HTLV)].
    Dorner F; Barrett PN; Schmidt BL; Bodemer W
    Wien Med Wochenschr; 1986 Apr; 136(7-8):181-8. PubMed ID: 2425498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etiology of AIDS: biological and biochemical characteristics of HTLV-III.
    Markham PD; Shaw GM; Salahuddin SZ; Hahn B; Sarngadharan MG; Gallo RC
    Adv Exp Med Biol; 1985; 187():13-34. PubMed ID: 2994417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS.
    Archibald DW; Zon L; Groopman JE; McLane MF; Essex M
    Blood; 1986 Mar; 67(3):831-4. PubMed ID: 3484980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pediatric AIDS: a disease spectrum causally associated with HTLV-III infection.
    Parks WP; Scott GB
    Cancer Res; 1985 Sep; 45(9 Suppl):4659s-4661s. PubMed ID: 2990704
    [No Abstract]   [Full Text] [Related]  

  • 55. Human retroviral env and gag polypeptides: serologic assays to measure infection.
    Kanner SB; Cheng-Mayer C; Geffin RB; Parks WP; Beltz GA; Arthur LO; Samuel KP; Papas TS
    J Immunol; 1986 Jul; 137(2):674-8. PubMed ID: 3014000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Case reports of 77 HTLV III/LAV-positive patients observed during one-year period. Preliminary note].
    Soranzo ML; Salassa B; Daziano E; Paggi GC
    Minerva Med; 1986 May; 77(20):897-900. PubMed ID: 3014379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A human T-lymphotropic retrovirus (HTLV-III) as the cause of the acquired immunodeficiency syndrome.
    Gallo RC; Wong-Staal F
    Ann Intern Med; 1985 Nov; 103(5):679-89. PubMed ID: 2996399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.
    Schüpbach J; Popovic M; Gilden RV; Gonda MA; Sarngadharan MG; Gallo RC
    Science; 1984 May; 224(4648):503-5. PubMed ID: 6200937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HTLV-III/LAV antibody status of spouses and household contacts assisting in home infusion of hemophilia patients.
    Lawrence DN; Jason JM; Bouhasin JD; McDougal JS; Knutsen AP; Evatt BL; Joist JH
    Blood; 1985 Sep; 66(3):703-5. PubMed ID: 2992640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.